Adding Nivolumab to Induction Chemotherapy Safe in Younger AML Patients

December 15, 2017

This video highlights a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia.

In this video, Farhad Ravandi-Kashani, MD, of the MD Anderson Cancer Center in Houston, discusses a phase II trial that tested the addition of nivolumab to combination induction chemotherapy of cytarabine and idarubicin for patients with newly diagnosed acute myeloid leukemia (AML). 

Ravandi-Kashani presented results of the study (abstract 815) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.